Orthofix Medical reported Q2 2025 financial results, beating earnings estimates with $203.1 million in revenue, representing 2.3% year-over-year growth. The company saw segment gains in Bone Growth Therapies and Orthopedics, with positive free cash flow and continued new product execution.

The global intramedullary nail market is expected to grow rapidly, driven by the rising incidence of bone fractures, particularly among the aging population, and advancements in surgical techniques. However, the market faces challenges such as high procedural costs, the need for skilled professionals, and competition from alternative fixation devices.

The global prosthetic disc nucleus market is expected to grow significantly, driven by the increasing prevalence of spine disorders and the rising demand for minimally invasive spine surgeries. Key players in the market include Zimmer Biomet, Medtronic, Orthofix Holdings, Spinal Kinetics, and Globus Medical.

A class action lawsuit has been filed against Orthofix Medical Inc. and certain current and former officers and directors, alleging that the offering materials for the merger with SeaSpine Holdings Corporation contained materially false and misleading statements and omissions regarding Orthofix's internal controls and compliance.

Bragar Eagel & Squire, P.C. is investigating potential claims against Orthofix Medical Inc. on behalf of long-term stockholders following a class action complaint alleging the company made false and misleading statements about certain members of its management team engaging in inappropriate conduct.

A class action lawsuit has been filed against Orthofix Medical Inc. and certain current and former officers and directors, alleging that the offering materials for the merger with SeaSpine Holdings Corporation contained materially false and misleading statements and omissions regarding Orthofix's internal controls and compliance.

A shareholder has filed a class action lawsuit against OrthoFix Medical Inc. (OFIX) on behalf of former SeaSpine Holdings Corporation shareholders who acquired OFIX stock in a merger. The lawsuit alleges that OFIX failed to disclose issues with its internal controls, compliance programs, and management misconduct at the time of the merger.

Rosen Law Firm is encouraging investors who purchased Orthofix Medical Inc. (OFIX) common stock between October 11, 2022 and September 12, 2023 to join a securities class action lawsuit before the October 21, 2024 deadline. The lawsuit alleges that the company made misleading statements and omissions regarding certain management team conduct.

Orthofix Medical Inc. is facing a securities fraud lawsuit for allegedly making false and misleading statements to the market regarding certain members of its management team engaging in inappropriate conduct. The lawsuit seeks to represent investors who purchased the company's securities during the class period.

Orthofix Medical Inc. (OFIX) is facing a securities fraud lawsuit filed by the Schall Law Firm. The lawsuit alleges that the company failed to disclose instances of inappropriate conduct by certain members of its management team, which led to the termination of those individuals and caused investor losses.

Rosen Law Firm reminds investors who purchased Orthofix Medical Inc. (NASDAQ: OFIX) common stock between October 11, 2022 and September 12, 2023 of the October 21, 2024 deadline to apply for lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that the defendants made misleading statements and omissions about Orthofix's operations, financial condition, and prospects.

Holzer & Holzer, LLC reminds investors of the October 21, 2024 lead plaintiff deadline in class action lawsuits against DexCom, Inc., Orthofix Medical Inc., and Spire Global, Inc. The lawsuits allege various issues related to the companies' financial reporting and management conduct.